Incyte
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 15 disclosed transactions, Incyte concentrates its licensing activity in Oncology, Hematology, and Dermatology. Incyte pays a 0.70x discount to market median. Their most common deal structure is Acquisition, with an average disclosed value of $1.3B. Most recent activity: 2026.
Pipeline coverage & gaps
Incyte has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| AcquisitionPrimary | 9 | $590M | $1.3B |
| Collaboration | 3 | $356M | $1.3B |
| License | 2 | $150M | $903M |
| Option | 1 | $35M | $910M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | Late-stage von Willebrand disease drug | Vega Therapeutics (Star Therapeutics) | von Willebrand disease / bleeding disorders | unknown | $1.3B | $2.0B |
| 2026 | Vega | Star Therapeutics | blood disorder | unknown | — | $2.0B |
| 2026 | VGA039 (Protein S modulator) | Vega Therapeutics | bleeding disorders | phase_3 | $1.3B | $2.0B |
| 2026 | factor VIII-independent bleeding disorder program | Vega Therapeutics | bleeding disorders | unknown | $730M | $2.0B |
| 2025 | PRT12396 (JAK2V617F program) | Prelude Therapeutics | JAK2V617F-positive myeloproliferative neoplasms (myelofibrosis, polycythemia vera, essential thrombocythemia) | preclinical | $35M | $910M |
| 2024 | EP262 and MRGPRX programs | Escient Pharmaceuticals | Atopic Dermatitis, Chronic Pruritus | phase_1 | $200M | $1.0B |
| 2024 | retifanlimab | MacroGenics, Inc. | merkel cell carcinoma | approved | $150M | $905M |
| 2024 | solid_tumors | MacroGenics | solid_tumors | phase_1 | $150M | $900M |
| 2024 | mds | Syndax Pharmaceuticals | mds | approved | $200M | $1.4B |
| 2024 | Escient Pharmaceuticals (EP262, EP547, and pipeline) | Escient Pharmaceuticals | chronic spontaneous urticaria | phase_2 | $750M | $750M |
| 2024 | Tafasitamab | MorphoSys | diffuse large B-cell lymphoma | approved | $425M | $425M |
| 2023 | ATR | Mirati Therapeutics | Pancreatic | discovery | $46M | $490M |
| 2022 | Auremolimab (VM6) | Villaris Therapeutics | vitiligo | preclinical | $70M | $1.4B |
| 2022 | tafasitamab (Monjuvi/Minjuvi) | MorphoSys | follicular lymphoma | approved | $750M | $2.0B |
| 2021 | Axatilimab | Syndax Pharmaceuticals | chronic graft-versus-host disease | phase_2 | $117M | $567M |
How this is computed
For each Incyte deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.633, clamped to [0.7, 1.5].